LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Public ClinicalTrials.gov record NCT02231164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma histology after failure of first-line platinum-based chemotherapy.
Study identification
- NCT ID
- NCT02231164
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 14, 2014 (Actual)
- Primary completion
- Dec 24, 2015 (Actual)
- Completion
- Dec 24, 2015 (Actual)
- Last update posted
- Feb 13, 2025
2014 – 2015
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1199.128.10032 Boehringer Ingelheim Investigational Site | Chandler | Arizona | — | — |
| 1199.128.10041 Boehringer Ingelheim Investigational Site | Fayetteville | Arkansas | — | — |
| 1199.128.10010 Boehringer Ingelheim Investigational Site | Highland | California | — | — |
| 1199.128.10044 Boehringer Ingelheim Investigational Site | Rancho Mirage | California | — | — |
| 1199.128.10080 Boehringer Ingelheim Investigational Site | Paducah | Kentucky | — | — |
| 1199.128.10016 Boehringer Ingelheim Investigational Site | Farmington | New Mexico | — | — |
| 1199.128.10013 Boehringer Ingelheim Investigational Site | Minot | North Dakota | — | — |
| 1199.128.10077 Boehringer Ingelheim Investigational Site | Blacksburg | Virginia | — | — |
| 1199.128.10011 Boehringer Ingelheim Investigational Site | Kennewick | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02231164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02231164 live on ClinicalTrials.gov.